Re-bleeding and mortality after lower gastrointestinal bleeding in patients taking anti-platelets or anti-coagulants
Clinical Gastroenterology and Hepatology Jan 10, 2018
Oakland K, et al. - The experts undertook this study to compare outcomes of patients receiving anti-platelets, anti-coagulants, or direct oral anti-coagulants (DOACs) who developed lower gastrointestinal bleeding (LGIB). In addition, they analyzed the effects of withholding these drugs on their course of bleeding. Antiplatelet drugs were correlated with an increased risk of re-bleeding in patients with LGIB. However, this was not true for warfarin or DOACs. During admission, withholding anti-platelets did not lead to a reduction in re-bleeding.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries